A novel pill that blocks the hormone aldosterone shows promise for lowering blood pressure and potentially delaying the progression of kidney disease in people with both conditions.
The preliminary findings were presented Saturday at an American Heart Association meeting in Baltimore and simultaneously published in the Journal of the American Society of Nephrology.
The Phase 2 clinical trial, known as FigHTN, found that the new medication, baxdrostat, yielded a roughly 5% reduction in systolic blood pressure when given to patients with chronic kidney disease who were unable to control their high blood pressure with existing medications.
Systolic blood pressure is the top number in a blood pressure reading. It measures pressure against your artery walls as the heart beats, according to the AHA.
Related
